MicroRNAs: a new therapeutic frontier for muscle wasting in chronic kidney disease.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 22846810.
- Also identified by DOI 10.1038/ki.2012.150.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Multiple microRNAs (miRs) are implicated in muscle cell differentiation and muscle mass regulation. Pharmacological agents targeting miR-486 and other miRs, involved in muscle mass regulation, could potentially be developed into therapeutic agents for muscle wasting. Muscle wasting is prevalent among patients with chronic kidney disease (CKD). Xu et al. showed that miR-486 mimetic ameliorated muscle wasting in mice with CKD. miR mimetics may represent a new therapeutic frontier for muscle wasting in CKD.
Medical subject headings
- Forkhead Transcription Factors
- MicroRNAs
- Muscle Proteins
- Muscle, Skeletal
- Muscular Atrophy
- Renal Insufficiency, Chronic